没有完全理解这个机制。一般来说，雌激素应该是不利的，应该用雌激素拮抗剂才对，为什么用受体激动剂TTC-352来治疗乳腺癌呢？看了一下原文，这样描述：TTC-352 is a selective human estrogen receptor partial agonist (ShERPA). TTC-352 is designed to treat metastatic ER+ breast cancers that have progressed on first-line endocrine therapy and a CDK4/6 inhibitor. TTC-352 is expected to be effective in breast cancer patients that develop resistance to endocrine therapy (est. 625,000 patients). 确实是雌激素受体部分激动剂(ShERPA)，以后再多研究研究
2020-08-29
没有完全理解这个机制。一般来说，#雌激素#应该是不利的，应该用雌激素拮抗剂才对，为什么用受体激动剂#TTC-352#来治疗#乳腺癌#呢？看了一下原文，这样描述：TTC-352 is a selective human estrogen receptor partial agonist (ShERPA). TTC-352 is designed to treat metastatic ER+ breast cancers that have progressed on first-line endocrine therapy and a CDK4/6 inhibitor. TTC-352 is expected to be effective in breast cancer patients that develop resistance to endocrine therapy (est. 625,000 patients). 确实是雌激素受体部分激动剂(ShERPA)，以后再多研究研究
2020-08-29
